+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liver And Kidney Disorders Drugs Market Research Reports

Moderate And Severe Chronic Kidney Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Moderate And Severe Chronic Kidney Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Acute Liver Failure - Pipeline Insight, 2025 - Product Thumbnail Image

Acute Liver Failure - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Hepatitis C Virus Infection- Pipeline Insight, 2025 - Product Thumbnail Image

Hepatitis C Virus Infection- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Nephrotic Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Nephrotic Syndrome - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 40 Pages
  • Global
From
Acute Pyelonephritis - Pipeline Insight, 2025 - Product Thumbnail Image

Acute Pyelonephritis - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Hepatitis B Virus Infection - Pipeline Insight, 2025 - Product Thumbnail Image

Hepatitis B Virus Infection - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 180 Pages
  • Global
From
Chronic Liver Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Liver Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Renal Cell Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Renal Cell Carcinoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Late-stage Chronic Kidney Disease (CKD) - Pipeline Insight, 2025 - Product Thumbnail Image

Late-stage Chronic Kidney Disease (CKD) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Nephropathic Cystinosis - Pipeline Insight, 2025 - Product Thumbnail Image

Nephropathic Cystinosis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Chronic Renal/Kidney Transplant Rejection - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Renal/Kidney Transplant Rejection - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Cystinosis- Pipeline Insight, 2025 - Product Thumbnail Image

Cystinosis- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Diabetic Kidney Disease (DKD) - Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Kidney Disease (DKD) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Distal Renal Tubular Acidosis (dRTA) - Pipeline Insight, 2025 - Product Thumbnail Image

Distal Renal Tubular Acidosis (dRTA) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
IgA Nephropathy- Pipeline Insight, 2025 - Product Thumbnail Image

IgA Nephropathy- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Primary Hyperoxyaluria - Pipeline Insight, 2025 - Product Thumbnail Image

Primary Hyperoxyaluria - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Liver Cirrhosis - Pipeline Insight, 2025 - Product Thumbnail Image

Liver Cirrhosis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Complement 3 Glomerulopathy (C3G) - Epidemiology Forecast - 2034 - Product Thumbnail Image

Complement 3 Glomerulopathy (C3G) - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 69 Pages
  • Global
From
Acute Kidney Injury (AKI) - Epidemiology Forecast - 2034 - Product Thumbnail Image

Acute Kidney Injury (AKI) - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 90 Pages
  • Global
From
Loading Indicator

The Liver and Kidney Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs to treat diseases and disorders of the liver and kidneys. These drugs are used to treat a variety of conditions, including hepatitis, cirrhosis, kidney failure, and other kidney-related diseases. The market is highly competitive, with many companies vying for market share. The market is driven by the increasing prevalence of liver and kidney diseases, as well as the development of new treatments and technologies. Additionally, the rising demand for better treatments and the increasing availability of generic drugs are also contributing to the growth of the market. Some of the major companies in the Liver and Kidney Disorders Drugs market include Pfizer, Merck, Novartis, Sanofi, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, and AbbVie. These companies are engaged in the development and production of drugs to treat liver and kidney diseases. Show Less Read more